rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Once-Weekly IcoSema vs Once-Daily IDegLira: Head-to-Head Insulin/GLP-1 Combination Comparison

RPEP-154082026Kandalam, Saikrishna; Benamar, Malik; Le Reun, Corinne; Rengger, Lauren; Gupta, Palvi; Nair, Sunita
evidence
The takeaway

Once-weekly IcoSema (insulin icodec + semaglutide) showed non-inferior or superior glycemic control and weight outcomes compared to once-daily IDegLira (insulin degludec + liraglutide) in T2D patients.

Weekly beats daily

Once-weekly IcoSema (insulin + semaglutide) matched or exceeded the daily combination's results — same efficacy, 7× less frequent injections

What the researchers found

IcoSema (weekly insulin icodec + semaglutide) showed non-inferior/superior glycemic and weight outcomes vs IDegLira (daily insulin degludec + liraglutide) in T2D.

Why it matters

Reducing injection frequency from daily to weekly dramatically improves treatment adherence — especially important for patients needing both insulin and GLP-1.

How the study worked

Clinical trial comparing once-weekly IcoSema vs once-daily IDegLira for HbA1c, body weight, and safety endpoints in T2D patients.

What this study cannot tell us

Head-to-head trial details in full paper. Follow-up duration affects conclusions.

How to read the evidence

Head-to-head clinical trial comparison.

When this study was published

Published in 2025.

The bigger picture

The evolution toward once-weekly combination therapies represents the ultimate simplification of complex diabetes treatment regimens.

Questions still open

  • Will IcoSema replace IDegLira as the preferred combination?
  • Does once-weekly dosing improve real-world adherence vs daily?
  • Would IcoSema be cost-effective vs IDegLira?

Common questions

Could one weekly injection replace a daily one?
Yes. IcoSema combines weekly insulin and semaglutide in one injection, matching or beating the daily IDegLira combination's blood sugar and weight results.
Is weekly dosing better?
For most patients, fewer injections mean better adherence. IcoSema provides the same benefits as daily IDegLira with 7× less frequent injections.

Read the original research

Efficacy and Safety of Once-Weekly IcoSema Versus Once-Daily IDegLira in People with Type 2 Diabetes: Systematic Literature Review and Network Meta-analysis.

Diabetes therapy : research, treatment and education of diabetes and related disorders

View on PubMed ↗Publisher’s paper ↗

Citation

Kandalam, Saikrishna; Benamar, Malik; Le Reun, Corinne; Rengger, Lauren; Gupta, Palvi; Nair, Sunita. (2026). Efficacy and Safety of Once-Weekly IcoSema Versus Once-Daily IDegLira in People with Type 2 Diabetes: Systematic Literature Review and Network Meta-analysis.. Diabetes therapy : research, treatment and education of diabetes and related disorders. https://doi.org/10.1007/s13300-026-01847-7